REQUEST A DEMO
Total
USD $0.00
Search more companies

EirGenix Inc. (Taiwan, China)

Main Activities: Research and Development in the Physical, Engineering, and Life Sciences
Full name: EirGenix Inc. Profile Updated: July 05, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Chinese Download a sample report

EirGenix is a contract development and manufacturing organization that provides high quality and cost-effectiveness service supporting its clients in development, analytical testing, and cGMP manufacturing of bio-pharmaceuticals from pre-clinical to commercial manufacturing.

Headquarters
No.101, Lane 169, Kangning St, Xizhi Dist
New Taipei City; New Taipei City;

Contact Details: Purchase the EirGenix Inc. report to view the information.

Website: http://www.eirgenix.com

Basic Information
Total Employees:
Purchase the EirGenix Inc. report to view the information.
Outstanding Shares:
Purchase the EirGenix Inc. report to view the information.
Financial Auditors:
Purchase the EirGenix Inc. report to view the information.
Incorporation Date:
December 21, 2012
Key Executives
Purchase this report to view the information.
Chairman
Ownership Details
Purchase this report to view the information.
9.02%
Purchase this report to view the information.
6.09%
Purchase this report to view the information.
5.02%
Purchase this report to view the information.
4.29%
Purchase this report to view the information.
0.76%
Subsidiaries
Eirgenix Europe Gmbh (Germany)
100%
Eirgenix Usa Icn. (Germany)
100%
Company Performance
Financial values in the chart are available after EirGenix Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Net sales revenue
26.19%
Total operating revenue
26.41%
Operating profit (EBIT)
0.18%
EBITDA
9.72%
Net Profit (Loss) for the Period
-14.04%
Total assets
-4.5%
Total equity
-8.42%
Operating Profit Margin (ROS)
24.86%
Net Profit Margin
8.66%
Return on Equity (ROE)
-1.21%
Debt to Equity Ratio
5.03%
Quick Ratio
-2.47%
Cash Ratio
1.3%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?